MiMedx in pact with Gunze for sales of EPIFIX in Japan

MiMedx Group announced that it has entered into an exclusive distribution agreement with GUNZE MEDICAL LIMITED , a subsidiary of Gunze Limited, for sales of EPIFIX in Japan. "Gunze Medical is a leading distributor of products used in a wide range of wound and surgical settings, including bioabsorbable devices and materials, such as sutures and sheet products," said the company. "Following the receipt of regulatory approval in 2021 and a favorable reimbursement rate decision just back in September 2022, we believe this partnership with Gunze will position EPIFIX for long-term success in this important market. ‘Since receiving regulatory approval, the Company has collaborated with local physician societies, including the Japanese Society for Foot Care and Podiatric Medicine, and approximately 20 national KOLs to drive initial awareness of EPIFIX in the market. In that time, over 250 physicians have been trained, several of whom have also treated their first patients with EPIFIX."We have been working to create commercial momentum in Japan for over a year, and Gunze Medical provides us with a strong, local commercial presence that shares our market vision and patient commitment," continued Mr. Newton. "We are mutually committed to delivering the sales and clinical support necessary to demonstrate the value of EPIFIX for patients in Japan suffering from hard-to-heal wounds each year."